Azacitidine plus ruxolitinib for higher-risk MDS/MPN
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests whether combining azacitidine and ruxolitinib can better control higher-risk bone marrow diseases (MDS/MPN, including CMML). It may help patients who are not good candidates for a stem cell transplant and who can safely take these medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a higher-risk diagnosis such as CMML, or another MDS/MPN type like aCML or MDS/MPN-U (based on specific risk scores).
- Your blood counts must be: neutrophils at least 2.0 × 10^9/L and platelets at least 25 × 10^9/L.
- You’re not a good candidate for a stem cell transplant (based on local standards).
- Your bone marrow blasts must be at least 5% if you have MDS/MPN types other than CMML.
- Your heart and organ tests must be safe (for example, heart pump strength on ultrasound at least 50%, and kidney/liver tests not too high).
- You must be able to sign consent and have a good enough daily function level (ECOG 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies a new treatment plan (decitabine-related medicine with other targeted drugs, depending on the arm) for adults with MDS/MPN overlap syndromes. It aims to improve control of the disease by targeting the abnormal bone marrow cells. Because it’s Phase 1/2, the main goal is to find safe dosing and see whether it helps responses.
This trial tests whether adding donated cord blood stem cells to azacitidine can improve outcomes for people with advanced MDS, CMML-2, or a certain type of AML. It may help by giving the treatment a stronger chance to control abnormal blood-forming cells.
This study tests a combination of two drugs, azacitidine and rotercept, for people with a type of blood cancer called myelodysplastic syndrome (MDS) that has a higher risk of progressing. The goal is to see if adding rotercept helps control the disease better than standard care.
This early-phase study tests a combination of ruxolitinib with venetoclax, with or without azacitidine, for adults whose acute myeloid leukemia (AML) has come back or does not respond to treatment. It may help by stopping cancer cells from growing and improving blood counts, with the exact plan guided by the study arm you’re assigned to.
This early-phase study tests whether combining two “epigenetic” medicines—azacitidine and decitabine—can improve outcomes for certain bone marrow cancers. It may help if you have a type of myelodysplastic syndrome (MDS) or MDS/MPN overlap that is expected to be sensitive to these medicines.
This study tests a mix of medicines (cladribine, low-dose cytarabine, and venetoclax) alternated with azacitidine and venetoclax to treat higher-risk CMML or MDS after prior treatment or when standard treatment may not work well. It may help by improving blood counts and controlling the disease.
Hear when a new MDS/MPN trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.